Research
Pioneering Study on Biotechnological Agents and JAK Inhibitors in VEXAS Syndrome Published
A groundbreaking new study has just been published in Frontiers in Pharmacology, shedding light on the efficacy and safety of biotechnological agents and Janus kinase inhibitors (JAKis) in patients with VEXAS syndrome.
Link to article
This study, titled "Efficacy and Safety Profile of Biotechnological Agents and Janus Kinase Inhibitors in VEXAS Syndrome: Data from the International AIDA Network VEXAS Registry", leverages real-world data from the International AIDA Network VEXAS Registry.
VEXAS syndrome, a recently identified systemic autoinflammatory disorder, presents significant diagnostic and treatment challenges. Based on experience with similar diseases, treatments targeting IL-1, IL-6, and TNF, along with JAK inhibitors, have been widely used. The study evaluates the global effectiveness and safety of these therapies in a cohort of 69 patients.
Key findings include:
- A complete response was observed in 23% of patients treated with IL-1 inhibitors, 15% with IL-6 inhibitors, 11% with TNF inhibitors, and 23.5% with JAKis.
- Significant reduction in prednisone dosage was noted with IL-1 inhibition (p=0.01), while other treatments showed variable steroid-sparing effects.
- Adverse events occurred in 21 patients, with three fatalities reported among those receiving JAKis.
The results highlight the promise of IL-1 and IL-6 inhibitors, alongside JAKis, as therapeutic options for VEXAS patients. However, the study underscores the necessity of careful monitoring to optimize treatment safety.